SPRC SciSparc Ltd
Price Chart
Executive Summary
SciSparc announced that its majority-owned subsidiary NeuroThera received conditional TSX approval for the acquisition of ~54% of CliniQuantum. The deal, valued at ~$9.46M in NeuroThera shares, has been extended to June 1, 2026, pending final conditions including an Israeli tax ruling. This is a small, contingent transaction with no direct financial impact on SciSparc's standalone operations.
Key Financial Metrics
Actionable Insight
The transaction is small and contingent; no material near-term catalyst for SPRC. Monitor for closing conditions (Israeli tax ruling, final TSX acceptance) by June 1, 2026. The deal does not change SciSparc's cash position or pipeline.
Key Facts
- NeuroThera received conditional TSX approval to acquire ~54% of CliniQuantum for 56.6M NeuroThera shares valued at ~$9.46M.
- The outside date for closing was extended from April 30, 2026 to June 1, 2026.
- CliniQuantum holds a license for quantum simulation/Monte Carlo methods applied to clinical trial data analysis.
- SciSparc's market cap is ~$3M; the deal is contingent and non-transformative for SciSparc's core business.
Financial Impact
~$9.46M in NeuroThera shares issued for 54% of CliniQuantum; no cash consideration.
Risk Factors
- Transaction may not close if conditions (tax ruling, TSX final acceptance) are not met.
- Consideration shares issued at floor price of $0.05 could dilute NeuroThera shareholders.
- No direct revenue or earnings impact for SciSparc; limited upside catalyst.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302879 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
6-K
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.71% | $11.44 (−0.87%) |
|
Jun 4, 2026
1d ago
|
Press Release
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.71% | $11.44 (−0.87%) |
|
May 29, 2026
7d ago
|
6-K
| $9.81 $10.59 | ▲ +7.95% | ▲ +7.68% | $11.44 (+16.62%) |
|
May 28, 2026
8d ago
|
Press Release
| $10.55 $9.81 | ▼ −7.01% | ▼ −7.26% | $11.44 (+8.44%) |
|
Mar 16, 2026
11w ago
|
Press Release
| $4.32 $4.62 | ▲ +6.94% | ▲ +6.67% | $11.44 (+164.81%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $4.73 $4.36 | ▼ −7.82% | ▼ −7.22% | $11.44 (+141.86%) |
|
Mar 10, 2026
12w ago
|
Press Release
| $4.02 $3.85 | ▼ −4.23% | ▼ −4.12% | $11.44 (+184.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access